KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Shares Repurchased (2016 - 2026)

Eli Lilly filings provide 15 years of Shares Repurchased readings, the most recent being $2.4 billion for Q1 2026.

  • On a quarterly basis, Shares Repurchased rose 96.33% to $2.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.3 billion, a 42.27% increase, with the full-year FY2025 number at $4.1 billion, up 64.32% from a year prior.
  • Shares Repurchased hit $2.4 billion in Q1 2026 for Eli Lilly, up from $1.5 billion in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $2.4 billion in Q1 2026 to a low of $446.1 million in Q3 2024.
  • Median Shares Repurchased over the past 5 years was $1.2 billion (2025), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Shares Repurchased: crashed 50.0% in 2023 and later skyrocketed 96.33% in 2026.
  • Eli Lilly's Shares Repurchased stood at $1.5 billion in 2022, then crashed by 50.0% to $750.0 million in 2023, then soared by 173.85% to $2.1 billion in 2024, then decreased by 26.59% to $1.5 billion in 2025, then skyrocketed by 56.26% to $2.4 billion in 2026.
  • The last three reported values for Shares Repurchased were $2.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $708.1 million (Q3 2025) per Business Quant data.